Global Head And Neck Cancer Therapeutics Market Forecast to Reach $2.8 Billion by 2029, Driven by 10.4% CAGR
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Head And Neck Cancer Therapeutics Market Valued at Present and by 2029?
The market for therapeutics in head and neck cancer has experienced swift expansion in the past years. The statistics indicate an increase from $1.71 billion in 2024 to $1.88 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 10.3%. The historical growth of this market can be traced back to factors such as tobacco and alcohol usage, infections caused by human papillomavirus (HPV), environmental impacts, and the progressive development of treatment methods.
The market size for therapeutics in head and neck cancer is projected to experience swift expansion in the upcoming years. It is estimated to reach “$2.8 billion by 2029, with a compound annual growth rate (CAGR) of 10.4%. The predicted rise during this forecast period can be linked to advancements in immunotherapy, precision medicine strategies, campaigns for early diagnosis and awareness, along with the worldwide aging population. Some key trends that will be seen in the forecast period are the growing role of targeted therapies, the adoption of less invasive surgical methods, the inclusion of palliative care, investigation of new biomarkers, and the focus on patient-centered care models.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12426&type=smp
#What Drivers Are Influencing Growth In The Head And Neck Cancer Therapeutics Market?
The rise in incidences of head and neck cancer is anticipated to stimulate the expansion of the head and neck cancer therapeutics market. Head and neck cancer is a condition whereby cells uncontrollably multiply in the tissues of the head and neck area. This surge in cases emphasizes the urgency for improved diagnosis and treatments that can target mutations and abnormal cancer cells. For example, Cancer Research UK, an independent cancer research body in the UK, predicted in 2023 that head and neck cancer incidents in the UK would see a 3% rise between 2023 and 2025. Furthermore, fatalities as a result of head and neck cancers are anticipated to surge by 12% within the same timeframe. Consequently, the rising prevalence of head and neck cancer is fuelling the growth of the head and neck cancer therapeutics market.
The head and neck cancer therapeutics market covered in this report is segmented –
1) By Type: Programmed Cell Death (PD) Inhibitors, Microtubule Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors
2) By Route Of Administration: Injectable, Oral
3) By Distribution Channel: Retail And Specialty Pharmacies, Hospital Pharmacies, Online Pharmacies
4) By Application: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Other Applications
Subsegments:
1) By Programmed Cell Death (PD) Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors
2) By Microtubule Inhibitors: Taxanes, Vinca Alkaloids
3) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Monoclonal Antibodies, Tyrosine Kinase Inhibitors
What Long-Term Trends Are Likely To Affect The Head And Neck Cancer Therapeutics Market?
Leading corporations in the domain of head and neck cancer therapeutics are intensifying their focus on unveiling new medicinal treatments for individuals who are dealing with head and neck cancer therapeutics. This approach to treatment involves utilizing pharmaceutical agents or medications to handle, control, or alleviate health conditions, illnesses, or symptoms in patients. To illustrate, Coherus BioSciences Inc, a biopharmaceutical organization based in the US, gained FDA clearance for its latest medication, ‘Loqtorzi’, also known as toripalimab-tpzi, in October 2023. The approval permitted the usage of the medication in conjunction with gemcitabine and cisplatin as the primary treatment for adults who had been diagnosed with recurring or metastatic, locally advanced nasopharyngeal carcinoma. During the trial phase, less than 20% of patients experienced adverse reactions, regardless of whether the treatment was used as an initial option or implemented as a single-agent therapy.
Which Companies Play A Key Role In The Development Of The Head And Neck Cancer Therapeutics Market?
Major companies operating in the head and neck cancer therapeutics market include Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi Aventis LLC, Bristol-Myers-Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Incyte Corporation, Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals PLC, Clinigen Group plc., Ligand Pharmaceuticals, Acceleron Pharma Inc., Taiho Pharmaceutical Co. Ltd., Boston Biomedical Inc., AB Science SA.
What Are The Key Regional Developments Shaping The Head And Neck Cancer Therapeutics Market?
North America was the largest region in the head and neck cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12426&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
